soul trial oral semaglutide cardiovascular outcomes nejm 2025 results Presented at ACC.25: Among participants with type 2 diabetes and disease, chronic kidney disease, or both, (14 mg) was associated with a lower risk of cardiovascular events than placebo Oral Semaglutide and Cardiovascular Outcomes

However, some people who quit smoking experience fluctuations with their weight

That's itthe new med went around the world like a juggernaut

Ultimately, on January 1st, 2024, the North Carolina State Health Plan made the decision to exclude GLP-1s for weight loss from coverage, while grandfathering in current utilizers

And whats clear, and fascinating, is that the side effects Im hearing about are evolving

They must also run a pregnancy test through a CLIA-certified lab each month during treatment and a month after treatment is completed

Derived from the p53 tumor-suppressor protein, PNC-27 exhibits a unique binding affinity for the MDM-2 protein found in the membranes of cancer cells